Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：27

作者：

Diedhiou, Demba ^{[1
,2
]}

Cuny, Thomas ^{[1
]}

Sarr, Anna ^{[2
]}

Diop, Said Norou ^{[2
]}

Klein, Marc ^{[1
]}

Weryha, Georges ^{[1
]}

机构：

[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France

[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal

来源：

ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期

关键词：

Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;

D O I：

10.1016/j.ando.2015.10.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.

引用

页码：650 / 657

页数：8

共 50 条

[21] The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis [J].

Xu, Fuxin ;

Wang, Yurun ;

Zhu, Xinjian .

CLINICAL THERAPEUTICS, 2024, 46 (03) :267-274

[22] Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women [J].

Chen, Yi ;

Zhu, Jun ;

Zhou, Yiqin ;

Peng, Jinhui ;

Wang, Bo .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[23] Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis [J].

Binkley, N. ;

Orwoll, E. ;

Chapurlat, R. ;

Langdahl, B. L. ;

Scott, B. B. ;

Giezek, H. ;

Santora, A. C. .

OSTEOPOROSIS INTERNATIONAL, 2021, 32 (01) :173-184

[24] Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis [J].

Diker-Cohen, Talia ;

Rosenberg, Dana ;

Avni, Tomer ;

Shepshelovich, Daniel ;

Tsvetov, Gloria ;

Gafter-Gvili, Anat .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (05)

[25] Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis [J].

Yanbeiy, Zeina A. ;

Hansen, Karen E. .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :2843-2852

[26] Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis [J].

Yang, Jia ;

Guo, Xiaobo ;

Cui, Zhongning ;

Guo, Huikang ;

Dong, Jia-Nan .

FRONTIERS IN ENDOCRINOLOGY, 2024, 15

[27] Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis [J].

Lewiecki, E. Michael .

DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 :79-91

[28] Osteoporosis in men: epidemiology and treatment with denosumab [J].

Sidlauskas, Kristel M. ;

Sutton, Emily E. ;

Biddle, Michael A. .

CLINICAL INTERVENTIONS IN AGING, 2014, 9 :593-601

[29] Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis [J].

Fontalis, Andreas ;

Kenanidis, Eustathios ;

Prousali, Efthymia ;

Potoupnis, Michael ;

Tsiridis, Eleftherios .

EXPERT OPINION ON DRUG SAFETY, 2018, 17 (04) :413-428

[30] Denosumab - a new option in the treatment of osteoporosis [J].

Franek, Edward .

ENDOKRYNOLOGIA POLSKA, 2011, 62 (01) :79-83

← 1 2 3 4 5 →